PDS Biotechnology (PDSB) AI Stock Analysis

• Market Cap: $54.35M
• Dividend Yield: N/A
• Average Volume (3M): 257.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.48
• Revenue Growth: N/A
• EPS Growth: 25.51%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 50
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 45,672,850
• 10 Day Avg. Volume: 201,805
• 30 Day Avg. Volume: 257,199
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.50
• Price Target Upside: 525.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

PDSB's overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. The company's strong clinical progress and cash position are significant positives, but financial sustainability and valuation concerns due to ongoing losses and reliance on external funding temper the outlook. Technical indicators suggest some positive momentum, albeit with caution.

Positive Factors

Clinical Outcomes

The combination therapy in the VERSATILE-002 study shows a clear clinical benefit, particularly in terms of objective response rate and survival metrics, potentially setting a new standard for HPV-targeted immunotherapy.

Clinical Trials

The initiation of the Phase 3 VERSATILE-003 trial to evaluate Versamune HPV in combination with pembrolizumab provides a promising step forward in treating HPV16-positive head and neck squamous cell carcinoma.

Regulatory Developments

The FDA's clearance of the IND application for Versamune MUC1 and PDS01ADC in MUC1-positive advanced colorectal carcinoma signifies a positive regulatory milestone.

Scientific Advancements

The ability of Versamune HPV + CRT to clear HPV16-positive cancer cells from the bloodstream faster than standard care is a significant scientific advancement.

Negative Factors

Financial Stability

The company is exploring additional funding opportunities to complete ongoing operations, including the VERSATILE-003 trial.

Funding Requirements

There is a need for additional funding to support the completion of crucial ongoing operations, impacting the company's financial strategy.

PDS Biotechnology Business Overview & Revenue Model

Company Description

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

How the Company Makes Money

PDS Biotechnology primarily generates revenue through strategic partnerships, collaborations, and licensing agreements with larger pharmaceutical companies and research institutions. These partnerships often involve milestone payments and royalties based on the development and commercialization of their Versamune®-based products. Additionally, the company may receive funding from government grants and research subsidies aimed at supporting advancements in cancer immunotherapy and vaccine development. As a clinical-stage company, PDS Biotech is still in the process of moving its products through clinical trials, with the potential for future revenue from product sales upon successful market approval.

PDS Biotechnology Financial Statement Overview

Summary

PDS Biotechnology's financials are typical of an early-stage biotech firm, with no revenue and ongoing losses due to high R&D costs. The strong cash position provides some immediate liquidity relief, but the negative cash flow and increasing debt highlight the need for future revenue generation. The reliance on external financing is a risk without clear paths to profitability.

Income Statement

PDS Biotechnology has reported no revenue over the last several years, indicating that the company is still in the development phase common to biotech firms. The absence of revenue and persistent negative EBIT and net income show ongoing operational losses. This is typical for biotech companies in early stages, but it poses significant financial risks if such trends continue without the introduction of revenue-generating products.

Balance Sheet

The company's balance sheet shows a relatively strong cash position with significant cash and short-term investments exceeding total debt, resulting in negative net debt, which is a positive indicator of liquidity. However, the equity has been declining due to ongoing losses, and the debt-to-equity ratio has increased over time, indicating rising leverage. The company’s equity ratio remains positive, reflecting more assets funded by equity than debt, but the trend suggests potential future financial strain.

Cash Flow

Free cash flow is consistently negative, reflecting high cash burn typical of biotech firms without revenue. Operating cash flow is negative and significantly exceeds net income, suggesting that operational activities consume more cash than they generate. The reliance on financing activities for cash flow stability poses a risk if external funding becomes less accessible.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-57.33K	-49.08K	-246.39K	-176.29K
	EBIT
-36.32B	-43.05M	-41.67M	-21.44M	-14.90M
	EBITDA
-36.32B	-40.08M	-41.62M	-21.19M	-14.67M
	Net Income Common Stockholders
-39.35B	-42.94M	-40.85M	-16.92M	-14.85M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
41.69B	56.56M	73.82M	65.24M	28.84M
	Total Assets
45.36B	59.39M	77.01M	67.20M	30.89M
	Total Debt
12.62B	23.85M	23.47M	490.35K	610.26K
	Net Debt
-29.07B	-32.71M	-50.35M	-64.75M	-28.23M
	Total Liabilities
26.35B	33.26M	33.01M	3.99M	3.76M
	Stockholders Equity
19.00B	26.13M	44.00M	63.21M	27.13M
Cash Flow		Free Cash Flow
-35.03B	-33.64M	-25.71M	-12.49M	-13.15M
	Operating Cash Flow
-35.03B	-33.64M	-25.71M	-12.49M	-13.15M
	Investing Cash Flow
-29.00M	0.00	0.00	0.00	0.00
	Financing Cash Flow
20.19B	16.38M	34.29M	48.89M	29.83M

PDS Biotechnology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.20
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PDSB, the sentiment is Negative. The current price of 1.2 is above the 20-day moving average (MA) of 1.19, below the 50-day MA of 1.21, and below the 200-day MA of 2.22, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 50.22 is Neutral, neither overbought nor oversold. The STOCH value of 11.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PDSB.

PDS Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	66 Neutral	$77.91M	2.46	-58.97%	―	36.45%	―
STRO	55 Neutral	$83.81M	―	-679.15%	―	-59.64%	-67.75%
Sector *	52 Neutral	$5.17B	3.59	-42.19%	2.82%	15.05%	-0.04%
PDSB	50 Neutral	$54.35M	―	-166.65%	―	―	25.51%
CUE	41 Neutral	$56.53M	―	-149.03%	―	69.16%	32.51%
PMVP	40 Underperform	$45.20M	―	-32.66%	―	―	21.33%
ACRV	36 Underperform	$38.57M	―	-54.07%	―	―	10.84%

PDS Biotechnology Corporate Events

PDS Biotechnology Enters $20M Securities Purchase Agreement

On April 30, 2025, PDS Biotechnology Corporation entered into a Securities Purchase Agreement to sell Senior Secured Convertible Debentures and warrants for a total purchase price of $20 million. The proceeds were used to retire the company’s existing debt under the Horizon Loan, with the remainder allocated for general corporate purposes. This agreement includes restrictions on variable rate transactions and imposes certain financial covenants, impacting the company’s financial strategy and market positioning.

Spark’s Take on PDSB Stock

According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.

PDSB’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. The company’s strong clinical progress and cash position are significant positives, but financial sustainability and valuation concerns due to ongoing losses and reliance on external funding temper the outlook. Technical indicators suggest some positive momentum, albeit with caution.

To see Spark’s full report on PDSB stock, click here.

PDS Biotechnology Director Sir Richard Sykes Retires

On April 22, 2025, Sir Richard Sykes, a member of the Board of Directors of PDS Biotechnology Corporation, announced his retirement and decision not to seek re-election at the company’s 2025 Annual Meeting of Stockholders. This change in the board’s composition may impact the company’s strategic direction and governance, potentially influencing its market positioning and stakeholder relations.

Spark’s Take on PDSB Stock

According to Spark, TipRanks’ AI Analyst, PDSB is a Underperform.

PDS Biotechnology’s stock score reflects a challenging financial position typical of early-stage biotech companies, with no revenue and high R&D expenses. Despite a strong cash position, the firm faces significant funding challenges. Technical analysis indicates a bearish trend, while valuation metrics highlight the lack of profitability. The earnings call provided some positive developments, such as promising trial results and fundraising, but also underscored financial challenges, balancing the overall outlook.

To see Spark’s full report on PDSB stock, click here.